<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902810</url>
  </required_header>
  <id_info>
    <org_study_id>12-205</org_study_id>
    <nct_id>NCT01902810</nct_id>
  </id_info>
  <brief_title>Protective Effects of Propranolol in Adults</brief_title>
  <official_title>Protective Effects of Propranolol in Adults Following Major Burn Injury: A Safety and Efficacy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Burn Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This efficacy and safety trial will examine the effects and safety of propranolol
      administered to adult patients with severe burn injury. The investigators hypothesize that
      propranolol will provide significant benefit to adults following severe burn injury at doses
      that are safe and do not increase risk of adverse infectious and non-infectious outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A safety and efficacy trial is needed in order to determine the safety of propranolol
      treatment in adult burn patients, identify which subpopulations may be most likely to
      benefit from propranolol treatment and to identify propranolol dose levels that are not only
      safe but potentially effective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardiac rate pressure product</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multiply the subjects resting heart rate and blood pressure measurements as the average per 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>time of randomization up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>mortality rates will be compared between placebo group and propranolol treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol by mouth given daily throughout hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth given daily throughout hospitalization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol by mouth given daily throughout hospitalization</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>metroprolol</other_name>
    <other_name>inderol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth given daily throughout hospitalization</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 20% Total Body Surface Area (TBSA) burn with anticipated operation need on
             admission

          -  Age ≥ 18 years

          -  Admission within 72 hours of injury

        Exclusion Criteria:

          -  Age &lt;18

          -  Patients unlikely to survive injury or with ;age = total burn size ≥ 130

          -  Electrical or deep chemical burn

          -  Malignancy currently undergoing treatment or history of cancer treatment within 5
             years

          -  History of HIV or AIDS

          -  Presence of anoxic brain injury that is not expected to result in complete recovery

          -  Currently treated for Chronic Obstructive Pulmonary Disease (COPD), asthma or other
             chronic pulmonary conditions

          -  History of Congestive Heart Failure (CHF) (ejection fraction &lt; 20%)

          -  Pre-injury medications including blocking agents (alpha or beta) or other
             anti-arrhythmic drugs

          -  Pregnant women

          -  Prisoners

          -  History of cardiac arrhythmia requiring medication

          -  Medical condition requiring glucocorticoid treatment

          -  Patients with concurrent conditions that in the opinion of the investigator may
             compromise patient safety or study objectives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Reed, RN</last_name>
    <phone>409-7706987</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Benjamin, RN</last_name>
    <phone>409-770-6731</phone>
    <email>dbenjami@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Mozingo, MD</last_name>
      <email>mozindw@surgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>David Mozingo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Burn Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Gamelli, MD</last_name>
      <email>rgamelli@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Gamelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G Patrick Kealey, MD</last_name>
      <email>gerald-kealey@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>G Patrick Kealey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shawn Fagan, MD</last_name>
      <email>Sfagan@partners.org</email>
    </contact>
    <investigator>
      <last_name>Shawn Fagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell Burn Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joe Bessey, MD</last_name>
      <email>pbb2001@cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Joe Bassey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sidney Miller, MD</last_name>
      <email>Sidney.Miller@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sidney Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Wolf, MD</last_name>
      <email>steven.wolf@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Benjamin, RN</last_name>
      <phone>409-770-6731</phone>
      <email>Dbenjami@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy L Reed, BSN</last_name>
      <phone>409-770-6987</phone>
      <email>ca2reed@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tam Pham, MD</last_name>
      <email>tpham94@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Tam Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Jeschke, MD</last_name>
      <email>Marc.Jeschke@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Jeschke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
